Trevena, Inc. (NASDAQ: TRVN) Investor Securities Class Action Lawsuit 10/11/2018

If you purchased a significant amount of shares of Trevena, Inc. (NASDAQ: TRVN) between May 2, 2016 and October 8, 2018, and / or if you purchased any NASDAQ: TRVN shares prior to May 2016 and continue to hold any of those shares, you have certain options and for certain investors are short and strict deadlines running. Deadline: December 10, 2018. NASDAQ: TRVN investors should contact the Shareholders Foundation, Inc.

To have your information reviewed for options and to recieve notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Company Name(s): 
Trevena
Case Name: 
Trevena Shareholder Class Action Lawsuit 10/11/2018
Case Status: 
Lawsuit Filed
Affected Securities
NASDAQ: TRVN
Lawsuit Overview
Type of Lawsuit: 
Shareholder Class Action
Date Filed: 
10/11/2018
Class Period Begin: 
05/02/2016
Class Period End: 
10/08/2018
Court of Filing: 
U.S. District Court for the Eastern District of Pennsylvania
Deadline To File for Lead: 
12/10/2018
Summary: 

An investor in shares of Trevena, Inc. (NASDAQ: TRVN) filed a lawsuit in the U.S. District Court for the Eastern District of Pennsylvania over alleged violations of Federal Securities Laws by Trevena, Inc. in connection with certain allegedly false and misleading statements made between May 2, 2016 and October 8, 2018.

Chesterbrook, PA Trevena, Inc., a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions.
On May 2, 2016, Trevena, Inc announced that it had “reached general agreement” with the FDA on key elements of its Phase 3 program for oliceridine (TRV130) and was “very pleased” with the outcome of its discussions with the FDA.
On October 9, 2018, minutes from the FDA’s April 28, 2016 meeting with Trevena, Inc were released and showed that the FDA:
• “did not agree with the proposed dosing in the Phase 3 studies”;

• “did not agree with the proposed primary endpoint”; and

• “did not agree with the proposed non-inferiority (NI) margin for comparing morphine to oliceridine.
• Shares of Trevena, Inc. (NASDAQ: TRVN) declined form $3.44 per share on October 5, 2018 to as low as $0.88 per share on October 10, 2018.

According to the complaint the plaintiff alleges on behalf of purchasers of Trevena, Inc. (NASDAQ: TRVN) common shares between May 2, 2016 and October 8, 2018, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between May 2, 2016 and October 8, 2018, Trevena misled its shareholders to believe that its April 28, 2016 End-of-Phase 2 Meeting with the United States Food and Drug Administration ("FDA") was far more successful than it actually was.